Shelley S. Moses

Point Therapeutics, Inc. develops drugs for the treatment of cancer and blood cell disorders. The company's PT-100 (talabostat) treats anemia and neutropenia (low levels of white blood cells), which can be caused by diseases or medical treatments, such as chemotherapy. The drugs stimulate production of proteins that build up the body's immune system against malignant tumors. Point Therapeutics, Inc. is located in Boston, MA.

BioGenetics, Inc. is engaged in the business of antimicrobials and biocides. It operates through two business segments: Antimicrobial and Biostatic and Biopharmaceutical Antibiotic and Antiviral product. The Antimicrobial and Biostatic segments products are used within the manufacturer's use products (MUP), retail, and institutional markets, which are sold through Nova BioGenetics, Inc. or its subsidiary, Nova Specialty Chemical, Inc. The Biopharmaceutical Antibiotic and Antiviral segment products are marketed through Nova BioPharmaceutical, Inc. The company was founded on April 23, 2001 and is headquartered in Sandy Springs, GA.